Combo Therapy for Advanced NSCLC Provides PFS Benefit Combo Therapy for Advanced NSCLC Provides PFS Benefit
Combining a TKI with chemo or an antiangiogenic agent may prolong PFS in advanced NSCLC with certain mutations. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Talking About Your Non-Small-Cell Lung Cancer Diagnosis
Sharing news of your lung cancer diagnosis isn’t easy. These steps can help the conversation go smoothly. (Source: WebMD Health)
Source: WebMD Health - December 14, 2022 Category: Consumer Health News Source Type: news
NSCLC: Advances in Treatment
The discovery that there are many types of non-small-cell lung cancer has led to many advances in how the disease is treated. Learn what you need to know.. (Source: WebMD Health)
Source: WebMD Health - December 14, 2022 Category: Consumer Health News Source Type: news
NSCLC: When You Need More Than One Treatment
Not long ago, chemotherapy was the only treatment for non-small -cell lung cancer. Now, doctors have many options. Sometimes, they combine them. (Source: WebMD Health)
Source: WebMD Health - December 14, 2022 Category: Consumer Health News Source Type: news
KRAZATI ® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
CARY, N.C., Dec. 14, 2022 — Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has been selected by Mirati therapeutics as one of two specialty pharmacies in a limited distribution network for KRAZATI® (adagrasib), which is indicated for the treatmen... (Source: McKesson News)
Source: McKesson News - December 14, 2022 Category: Information Technology Source Type: news
Dedicated care team guides patient through lung cancer with latest treatment
On the same December day in 2016, Patty Jones celebrated the birth of her ninth grandchild and learned she had advanced non-small cell lung cancer. “I knew I had to get this cancer behind me because I had another grandchild to watch grow up and graduate from school,” said Jones, who credits her family, God and the care she received at Atrium Health Wake Forest Baptist’s Comprehensive Cancer Center for saving her life.
“God opened all t he doors for me to be introduced to the Comprehensive… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 14, 2022 Category: American Health Authors: Atrium Health Wake Forest Baptist Source Type: news
Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC
It becomes the second KRAS-targeted therapy for use in patients with non –small cell lung cancer (NSCLC) whose tumors have this mutation.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 13, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Krazati (adagrasib) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO, Dec. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 12, 2022 Category: Drugs & Pharmacology Source Type: news
Liquid Biopsies in NSCLC May Prolong Patients' Lives Liquid Biopsies in NSCLC May Prolong Patients' Lives
Patients with ctDNA alterations who received targeted therapy on the basis of these alterations survived longer than patients who did not receive targeted therapy. (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
3 Top Stocks to Buy Hand Over Fist Before the End of 2022
You don't have to be in a hurry when it comes to buying stocks. At least that's true most of the time. Whether you invest sooner or later usually doesn't matter all that much over the long run. However, there are some examples where a sense of urgency could be appropriate to some extent. Here are…#elilillyelililly #lly #nsclc #occidental #oxy #ttfields #cms #occidentalpetroleum #berkshirehathaway #novocure (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2022 Category: Consumer Health News Source Type: news
In Early-Stage NSCLC, Give Nivolumab Before or After Surgery? In Early-Stage NSCLC, Give Nivolumab Before or After Surgery?
Dr Mark Kris discusses the choice between neoadjuvant and adjuvant nivolumab for patients with early-stage lung cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2022 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Where Are Checkpoint Inhibitors Standard of Care for NSCLC? Where Are Checkpoint Inhibitors Standard of Care for NSCLC?
Dr Mark Kris discusses the use of checkpoint inhibitors in the adjuvant and neoadjuvant settings for patients with non-small cell lung cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2022 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
More Frequent Scans Not Linked to Improved Survival After Lung Cancer Surgery
More frequent surveillance not linked to longer recurrence - free, overall survival in pathologic stage I non - small cell lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 7, 2022 Category: Cancer & Oncology Tags: Oncology, Pulmonology, Radiology, Surgery, Journal, Source Type: news
